Gemcitabine therapy for unresectable pancreatic cancer in elderly patients

Journal of Japanese Society of Gastroenterology

Volumn 107, Issue 3, 2010, Pages 396-406

  Katakura, Yoshiki ^a   Nakahara, Kazunari ^a   Kobayashi, Minako ^a   Adachi, Seitaro ^a   Izawa, Naoki ^a   Noguchi, Yohei ^a   Nakatsu, Satoko ^a   Sato, Yoshinori ^a   Takagi, Rei ^a   Itoh, Fumio ^a  

^a ST MARIANNA UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CA 19-9 ANTIGEN; GEMCITABINE;

ADULT; AGED; ARTICLE; CANCER STAGING; CANCER SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG SAFETY; DRUG WITHDRAWAL; FEMALE; GROUPS BY AGE; HUMAN; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; POOR GENERAL CONDITION; THERAPY EFFECT; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

AGED; AGED, 80 AND OVER; ANTIMETABOLITES, ANTINEOPLASTIC; DEOXYCYTIDINE; FEMALE; HUMANS; MALE; MIDDLE AGED; PANCREATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 77950817184     PISSN: 04466586     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (26)

1. Guideline for exploratory clinical trial of combination chemotherapy. Int J Clin Oncol 9 (supple) : 56-57: 2006
2. Shepherd FA. Abratt RP. Anderson H. et al: Gemcitabine in the treatment of elderly patients with advanced non-small cell lung cancer. Semin Oncol 24 (Suppl) ; S7-50-S7-55: 1997 (Pubitemid 27255927)
3. Martin C, Ardizzoni A, Rosso R: Gemcitabine: safety profile and efficacy in non-small cell lung cancer unaffected by age. Aging 9; 297-303: 1997 (Pubitemid 27450503)
4. Bramhall SR, Schulz J. Nemunaitis J. et al: A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161-167: 2002
5. Colucci G. Giuliani F. Gebbia V, et al: Gemcitabine alone or with cisplatin for the treatment of patients with locally advanced and/or metastatic pancreatic carcinoma: a prospective, randomized phase HI study of the Gruppo Oncologia dell' Italia Meridionale. Cancer 94; 902-910: 2002 (Pubitemid 34150843)
6. Berlin JD, Catalano P. Thomas JP. et al: Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trial E2297. J Clin Oncol 20: 3270-3275: 2002 (Pubitemid 34831525)
7. Van Cutsem E. van de Velde H. Karasek P. et al: Phase III trial of gemcitabine plus tipifarnib compared with gemcitabine plus placebo in advanced pancreatic cancer. J Clin Oncol 22; 1430-1438: 2004 (Pubitemid 41103625)
8. Rocha Lima CM, Green MR, Rotche R, et al: Irinotecan plus gemcitabine results in no survival advantage compared with gemcitabine monotherapy in patients with locally advanced or metastatic pancreatic cancer despite increased tumor response rate. J Clin Oncol 22; 3776-3783: 2004 (Pubitemid 41095218)
9. Oettle H. Richards D, Ramanathan RK. et al: A phase HI trial of pemetrexed plus gemcitabine versus gemcitabine in patients with unresectable or metastatic pancreatic cancer. Ann Oncol 16: 1639-1645: 2005 (Pubitemid 41510138)
10. Louvet C, Labianca R. Hammel P. et al: Gemcitabine in combination with oxaliplatin compared with gemcitabine alone in locally advanced or metastatic pancreatic cancer: results of a GERCOR and GISCAD phase III trial. J Clin Oncol 23: 3509-3516: 2005 (Pubitemid 46243495)
11. Heinemann V, Quietzsch D, Gieseler F, et al: Randomized phase III trial of gemcitabine plus cisplatin compared with gemcitabine alone in advanced pancreatic cancer. J Clin Oncol 24; 3946-3952: 2006 (Pubitemid 46630743)
12. Moore MJ, Goldstein D, Hamm J, et al: Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25: 1960-1966: 2007 (Pubitemid 46972777)
13. Herrmann R. Bodoky G. Ruhstaller T. et al: Gemcitabine plus capecitabine compared with gemcitabine alone in advanced pancreatic cancer: a randomized, multicenter, phase III trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group. J Clin Oncol 25; 2212-2217: 2007 (Pubitemid 46954645)
14. Ueno H, Okusaka T. Ikeda M. et al: An early phase II study of S-1 in patients with metastatic pancreatic cancer. Oncology 68; 171-178: 2005 (Pubitemid 41158973)
15. Okusaka T. Funakoshi A, Furuse J. et al: A late phase II study of S-1 for metastatic pancreatic cancer. Cancer Chemother Pharmacol 61; 615-621: 2008
16. Nakamura K. Yamaguchi T. Ishihara T. et al: Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 92; 2134-2139: 2005 (Pubitemid 40966247)
17. Ueno H. Okusaka T. Ikeda M. et al: A phase I study of combination chemotherapy with gemcitabine and oral S-1 for advanced pancreatic cancer. Oncology 69; 421-427: 2005 (Pubitemid 41797919)
18. Nakamura K, Yamaguchi T, Ishihara T. et al: Phase II trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer. Br J Cancer 94: 1575-1579: 2006 (Pubitemid 43924916)
19. Morizane C. Okusaka T, Furuse J, et al: A phase II study of S-1 in gemcitabine-refractory metastatic pancreatic cancer. Cancer Chemother Pharmacol 63: 313-319: 2008